CD38 and AL amyloidosis: The clinical efficacy of anti-CD38 monoclonal antibodies, such as daratumumab and isatuximab, has been demonstrated in various phases of multiple myeloma treatment, including newly diagnosed, relapsed, and refractory settings (47–53).